治療方案

Viagra®威而鋼®

亞洲銷售No.1

Viagra®威而鋼®（在香港俗稱「偉哥」，通用名稱：西地那非sildenafil）是一種能放鬆血管的第五型磷酸二酯酶PDE5（phosphodiesterase type 5）抑制劑，適合關注硬度不足的成年男士。2,3

為何選擇Viagra®威而鋼®

威而鋼®為全球第一種獲美國食品藥物管理局FDA（Food and Drug Administration）及歐洲藥物管理局EMA（European Medicines Agency）認可用於治療勃起功能障礙的口服藥物，全球超過6,600萬名男士使用，為亞洲銷售No.1 。1,4,5

威而鋼®獲超過120項臨床研究實證，其安全性和效用均為信心之選：超過96%男士使用威而鋼®四年後滿意藥效、其藥力快至14分鐘見效、藥效更可維持4至5小時。2,3,6–9

  • 參考資料PM-COR-22-112808

    1. IQVIA MIDAS MAT 2020 Q1 Asia Sales, (G04E) ED Market
    2. Viagra® (sildenafil citrate) 25 mg, 50 mg & 100 mg Tablets. Prescribing Information. Viatris Healthcare Hong Kong: Version February 2021.
    3. Viagra® (sildenafil citrate) 50 mg Orodispersible Tablets. Prescribing Information. Viatris Healthcare Hong Kong: Version February 2021.
    4. Three decades of Viagra. The Pharmaceutical Journal. 2017. Available at: https://pharmaceutical-journal.com/article/infographics/three-decades-of-viagra. Accessed on February 13, 2023.
    5. IMS Data, Data on file. New York, NY; June 2017.
    6. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-255.
    7. McMurray JG, Feldman RA, Auerbach SM, Deriesthal H, Wilson N, Multicenter Study Group. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007;3(6):975-981.
    8. Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng LJ, Deriesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology. 2003;62(3):400-403.
    9. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2002;53:61S-65S.

相關疾病

泌尿科疾病

了解更多 ...